Skip to content

Our Company
Pipeline
News
Investors
Contact

ESSA PHARMA, INC. HAS BEGUN DEVELOPMENT OF A SECOND GENERATION ANITEN COMPOUND FOR THE TREATMENT OF HORMONE-DRIVEN CANCER

Investors

Investor Contact

Alan Lada
Vice President, Solebury Trout
[email protected]

Subject*

Name*

Email*

Phone

Questions / Comments

Investors
Corporate Governance
Events & Presentations
Financial Information
Stock Information
Analyst Coverage
Investor Contact
Publications

Home

Our Company
Executive Team
Board of Directors
Scientific Advisors
Careers

Pipeline
Androgen Receptor
Aniten Compounds
Publications

News
Press Releases

Investors
Corporate Governance
Events & Presentations
Financial Information
Stock Information
Analyst Coverage
Investor Contact

Contact
Locations & Inquiries

© ESSA Pharma, Inc. 2019. All rights reserved. Privacy Policy | Terms & Conditions | Code of Conduct